Infectious Disease Point-of-care (POC) Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Technique (Lateral Flow Immunoassay, Agglutination Test and Others), By Disease (HIV, Hepatitis B Virus, Pneumonia/Streptococcus Associated Infections, RSV, Influenza, Clostridium Difficile Infections, Hepatitis C Virus, Methicillin-Resistant Staphylococcus Aureus, Tuberculosis, and Others), By Disease, COVID-19 Point-of-care (POC) Diagnostics, By End User (Hospital Bedside, Physicians Office Lab, Urgent Care & Retail Clinics and Others), and Regional Forecast, 2023-2030

ATTRIBUTE

DETAILS

Study Period

2019-2030

Base Year

2022

Estimated Year   

2023

Forecast Period

2023-2030

Historical Period

2019-2021

Unit

Value (USD Billion)

Growth Rate

CAGR of -2.8% from 2023-2030

 Segmentation

By Technique

• Lateral Flow Immunoassay (LFIA)


• Agglutination Test


• Flow-through test/Immunoconcentration Assay


• Molecular Diagnostics


• Others

By Disease

• HIV


• Hepatitis B Virus


• Pneumonia/Streptococcus Associated Infections


• Respiratory Syncytial Virus (RSV)


• Influenza


• Clostridium Difficile Infections (CDI)


• Hepatitis C Virus


• Methicillin-Resistant Staphylococcus Aureus (MRSA)


• Tuberculosis (TB)


• COVID-19


• Others

By End-User

• Hospital Bedside


• Physician's Office Lab


• Urgent Care & Retail Clinics


• Home & Self-testing


• Nursing Home


• Others

By Geography

• North America (U.S. and Canada)


• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)


• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)


• Latin America (Brazil, Mexico, and Rest of Latin America)


• Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)